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SUMMARY 1 
Type 1 diabetes (T1D) results from the autoimmune destruction of insulin-producing β cells. A 2 
comprehensive picture of the changes during T1D development is lacking due to limited sample 3 
availability, inability to sample longitudinally, and the paucity of technologies enabling 4 
comprehensive tissue profiling. Here, we analyzed 1,581 islets from 12 human donors, including 5 
eight with T1D, using imaging mass cytometry (IMC). IMC enabled simultaneous measurement 6 
of 35 biomarkers with single-cell and spatial resolution. We performed pseudotime analysis of 7 
islets through T1D progression from snapshot data to reconstruct the evolution of β cell loss and 8 
insulitis. Our analyses revealed that β cell destruction is preceded by a β cell marker loss and by 9 
recruitment of cytotoxic and helper T cells. The approaches described herein demonstrate the 10 
value of IMC for improving our understanding of T1D pathogenesis, and our data lay the 11 
foundation for hypothesis generation and follow-on experiments.  12 
 2 
 
INTRODUCTION 13 
Type 1 diabetes (T1D) is a chronic condition thought to result from an autoimmune attack on 14 
insulin-producing β cells in the pancreatic islets of Langerhans (Atkinson et al., 2014). The 15 
disorder, characterized by overt hyperglycemia, develops from a poorly understood combination 16 
of genetic and environmental factors and is thought to involve complex interactions between islets 17 
and cells of the immune system (Boldison and Wong, 2016). The study of human T1D has been 18 
limited by sample availability. Further, imaging of the pancreatic islets cannot be performed in 19 
vivo, and pancreatic biopsies, which would enable longitudinal studies of the changes of islet cell 20 
composition and cell-cell interactions, are not undertaken due to the associated investigational 21 
risks. Consequently, much of our knowledge regarding T1D pancreas pathology is derived from 22 
mouse models and limited analysis of individual specimens obtained from autopsy collections of 23 
human pancreata (Gepts, 1965; Foulis and Stewart, 1984). To enable more systematic studies of 24 
human pancreatic T1D tissue, biobanks such as the Network for Pancreatic Organ donors with 25 
Diabetes (nPOD) or the Human Pancreas Analysis Program (HPAP) (Campbell-Thompson et al., 26 
2012a; Marchetti et al., 2018) have been established to collect tissues from organ donors. 27 
 In recent years, studies of human pancreas samples from these biobanks have provided 28 
valuable information regarding the pathogenesis and natural history of this disease. For example 29 
these analyses revealed the presence of islet-specific autoreactive CD8+ T cells in the pancreata 30 
of donors with T1D (Coppieters et al., 2012). It has also become evident that insulitis is less 31 
aggressive amongst T1D patients than it is in mouse models of T1D (Meier et al., 2005; 32 
Coppieters et al., 2012). Heterogeneity is observed on the cellular level, as the loss of functional 33 
β cell mass is not only caused by β cell destruction but also by dysfunctional β cells (Chen et al., 34 
2017). On the individual pancreas level, insulitis often occurs in a lobular fashion and even islets 35 
in proximity show the presence and absence of insulitis (Gianani et al., 2010; Rodriguez-Calvo et 36 
al., 2015). A large degree of inter-patient heterogeneity is observed in terms of insulitis frequency 37 
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and composition, residual β cell mass, and pace of β cell destruction (Campbell-Thompson et al., 38 
2016), with insulitic lesions sometimes persisting for decades after diagnosis (Meier et al., 2005; 39 
Coppieters et al., 2012). 40 
 Despite these findings, our understanding of T1D progression in human patients is limited. 41 
An understanding of how cell types, cell states, and cell-cell interactions evolve during T1D 42 
development is essential to designing strategies to cure or halt this disorder. The lack of a 43 
comprehensive spatially resolved cellular analysis of the T1D lesion is due, at least in part, to the 44 
fact that only recently have highly multiplexed tissue imaging technologies emerged that allow for 45 
comprehensive studies of tissue from rare donor samples. These approaches include imaging 46 
techniques that are based on cyclic immunofluorescence (Schubert et al., 2006; Gerdes et al., 47 
2013; Zrazhevskiy and Gao, 2013; Lin et al., 2015; Goltsev et al., 2018; Gut et al., 2018), epitope-48 
targeted mass spectrometry (Angelo et al., 2014; Giesen et al., 2014), and RNA detection (Ke et 49 
al., 2013; Lee et al., 2014; Chen et al., 2015; Schulz et al., 2018). These methods provide a 50 
comprehensive view of marker distribution and tissue composition and are, therefore, poised to 51 
unlock some of the mysteries surrounding the pathogenesis of T1D and other complex disorders 52 
(Bodenmiller, 2016).  53 
 Here we used imaging mass cytometry (IMC) to analyze pancreas tissue from four control 54 
organ donors as well as four at onset and four with long-term T1D. IMC combines laser ablation 55 
with mass cytometry to enable simultaneous evaluation of up to 50 biomarkers from tissue 56 
sections stained with metal-tagged antibodies (Giesen et al., 2014). Using IMC data, we 57 
generated a map of islet heterogeneity as well as interactions between islet and immune cells. 58 
Pseudotime analysis at the islet-level enabled us to reconstruct islet evolution through T1D 59 
progression from the snapshot data from the 12 donors. These analyses revealed that a large 60 
fraction of islets from patients with recent-onset T1D retain a near-normal fraction of β cells but 61 
that the phenotype of these β cells is altered prior to β cell destruction. Finally, we investigated 62 
the dynamics of islet-associated immune cells and the evolution of cell-cell interactions during 63 
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T1D progression. We observed that, although association between islet cells and immune cells 64 
is rare, both cytotoxic and helper T cells are simultaneously recruited to β cell-rich islets during 65 
T1D onset, indicating the assembly of a destructive immune motif.  66 
 5 
 
RESULTS 67 
Preprocessing of Human T1D Samples and Image Acquisition 68 
In IMC, tissue sections are labeled with metal-conjugated antibodies (Figure 1A). During image 69 
acquisition, a laser ablates the tissue spot-by-spot at a resolution of 1 μm, and the clouds of tissue 70 
particles are analyzed by mass cytometry. The metal composition of the ablated tissue and thus, 71 
by inference, the antibody and epitope content is used to create images pixel-by-pixel, each pixel 72 
corresponding to one laser shot (Giesen et al., 2014). To enable IMC measurement of pancreas 73 
specimens from human donors with T1D, we designed a novel panel of 35 metal-tagged 74 
antibodies targeting key islet cell antigens as well as immune cell markers (Table 1 and STAR 75 
methods). 76 
 We selected 12 cases from the nPOD biorepository to represent recent-onset T1D (< 0.5 77 
years, N = 4), long-standing T1D duration (≥ 8 years, N = 4), and controls without diabetes (N = 78 
4) and for each donor analyzed two sections originating from different anatomical regions of the 79 
pancreas (tail, body, or head) (Table S1). Because the speed of data acquisition prevents imaging 80 
of entire pancreas sections, we used immunofluorescence (IF) to perform a pre-selection of areas 81 
of interest (Figure S1A and STAR Methods). We then stained the same sections with metal-82 
labeled primary antibodies (Table 1) and imaged the selected areas by IMC. Our measurements 83 
yielded 845 multiplexed images that included 1581 islets (each with ≥ 10 cells); data were 84 
obtained in 37 channels corresponding to the 35 antibodies and two DNA counterstains in our 85 
panel (Figure S2). 86 
 87 
Extraction of Single-Cell and Islet Level Data 88 
Cell segmentation is essential to recover quantitative single-cell information from highly 89 
multiplexed images (Carpenter et al., 2006). We used supervised machine learning and computer 90 
vision algorithms to generate cell and islet segmentation masks, which represent pixels belonging 91 
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to the same cell or islet, respectively (Figure 1B, Figure S3 and STAR Methods) (Kamentsky et 92 
al., 2011; Sommer et al., 2011). Applying these masks over high-dimensional pictures allowed 93 
retrieval of phenotypic and functional marker expression, spatial information and neighborhood 94 
information. We also combined cell and islet masks to extract additional information, such as the 95 
distance from cells to the islet rim (Figure 1C-H). Although cell populations can be defined using 96 
clustering approaches, we sought a more accurate way to define cell types in our dataset and 97 
turned to supervised machine-learning approaches (Figure S3 and STAR Methods) (Sommer et 98 
al., 2011). We first trained a classifier to segregate cells into four main categories (i.e., islet, 99 
immune, exocrine, other) and then performed sub-classification within each category in order to 100 
identify individual cell types. Together, these approaches enabled extraction of a wide range of 101 
biological information that can be explored in downstream data analyses to gain deeper insights 102 
into cell phenotypes and tissue function. 103 
 104 
Evolution of Islet Cellular Composition and Architecture during T1D Progression 105 
Even within a single pancreas, islet size and cell type composition are highly heterogeneous 106 
(Brissova et al., 2005; Cabrera et al., 2006). Whether this heterogeneity influences T1D 107 
progression remains unknown. We, therefore, sought to determine how islet structure and cell 108 
type composition change when T1D progresses. The 1581 imaged islets displayed striking 109 
heterogeneity in terms of cell number and cell type composition (Figure 2A). We also observed 110 
large inter-donor variations (Figure 2B). As compared to non-diabetic controls, β cell fraction was 111 
reduced by 62% in donors with recent-onset T1D. Remarkably, two of the four samples from 112 
donors at T1D onset had a proportion of β cells approaching those observed in some of the non-113 
diabetic individuals (nPOD cases 6414 and 6380 had 57% and 72% of the average β cell fraction 114 
in control donors, respectively). As expected, however, pancreata from donors with prolonged 115 
disease duration were almost entirely devoid of β cells. Next, we examined intra-pancreas 116 
heterogeneity to determine whether different regions of the same pancreas differed in cell type 117 
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composition. Within each pancreas, islet cellular composition was remarkably homogenous. We 118 
observed a significant difference in β cell loss between the pancreas body and tail in only one of 119 
the donors with recent disease onset (nPOD case 6380) (Figure 2C). Previous reports indicate 120 
that the head region of the pancreas is enriched in γ cells (Malaisse-Lagae et al., 1979; Brereton 121 
et al., 2015). We made a similar observation in the only pancreas head section analyzed (nPOD 122 
case 6264). 123 
 Next, we examined how cell type composition varied with islet size. We found that in non-124 
diabetic donors, the percentage of β cells was highest in islets of intermediate size, and lowest in 125 
very small (< 10 cells) and very large (> 250 cells) islets (Figure 2D). The distribution of α cells 126 
exhibited the opposite trend, whereas δ cell fractions were fairly constant. We noticed a similar 127 
pattern in islets from recent-onset donors, whereas the few residual β cells found in donors with 128 
long-standing T1D were most often found isolated or in very small islets, in line with previous 129 
observations (Wasserfall et al., 2017). 130 
Finally, we measured the distance of islet cell subsets to the islet rim and to blood vessels 131 
in order to evaluate human islet architecture. Because the risk of overestimating distances in two-132 
dimensional images increases with the measured distance, we limited the range of our analyses 133 
to cells located within 25 μm of islet rims or blood vessels. We observed that in non-diabetic 134 
donors, α cells were preferentially located at the islet periphery than in the islet core, whereas β 135 
cells exhibited an opposite tropism (Figure 2E). Similarly, α cells were more frequently found along 136 
blood vessels than were β cells (Figure 2F). These findings support earlier observations (Bosco 137 
et al., 2010; Brereton et al., 2015). Further, we observed that this islet organization is globally 138 
conserved between non-diabetic and recent-onset T1D donors, whereas in islets from donors 139 
with long-standing T1D architecture is altered due to β cell loss (Figure 2E-F). 140 
 141 
 8 
 
Evolution of Islet Profiles during T1D Progression 142 
It would be ideal to observe changes of cell phenotypes and cell-cell interactions that take place 143 
inside islets during T1D progression. Unfortunately, the study of T1D pancreas pathology relies 144 
on samples collected post-mortem, only allowing for snapshot analysis. To generate a time 145 
resolved map of T1D pathogenesis, we sought to reconstruct islet evolution from cross-sectional 146 
data. To achieve this, we first determined islet expression profiles by quantifying abundances of 147 
12 islet-expressed markers, averaged over the islet area. Hierarchical clustering of islet profiles 148 
distinguished non-diabetic from diseased donors but did not clearly separate recent-onset donors 149 
from those with long-standing disease (Figure S4A). To visualize individual islet profiles, we 150 
performed a dimensionality reduction analysis with tSNE (van der Maaten and Hinton, 2008). 151 
tSNE confirmed that islets from donors with or without T1D exhibited clearly distinct profiles 152 
(Figure 3A and Figure S4B), but the separation between islets from recent-onset and long-153 
duration T1D donors was only partial. In particular, a large cluster composed of islets from donors 154 
with different disease durations was found (Figure 3A, circled in dotted blue line). These results 155 
indicated that islets from donors at very different T1D stages can have similar profiles. 156 
 To better understand how islet expression profiles change with disease progression, we 157 
performed a pseudotime analysis using the trajectory inference algorithm SCORPIUS (Figure 3B 158 
and Figure S4C) (Cannoodt et al., 2016; Saelens et al., 2018). This approach revealed that the 159 
abundance of β cell markers decreased with pseudotime progression (Figure 3C and Figure S4D). 160 
Strikingly, visualizing islet distribution over pseudotime revealed a bimodal distribution of islets 161 
from donors with recent T1D onset (Figure 3D, left). To analyze this observation in more detail, 162 
we calculated the density distributions in the assigned pseudotime for each stage (Figure 3D, 163 
right). We defined three pseudostages based on the intersections between these distributions, 164 
thereby allowing stratification of islets according to their individual expression profiles rather than 165 
on donor disease duration. Using this approach, islets from non-diabetic donors were distinct from 166 
islets from donors with T1D, but also about half of the islets from donors categorized as recent 167 
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onset exhibited the phenotype found in long-duration T1D (Figure 3D). We observed a similar 168 
bimodal distribution in samples from each of the four donors with recent-onset T1D (Figure S4E). 169 
Together these analyses revealed that islet profiles do not necessarily correlate with disease 170 
duration. 171 
 Because pseudotime was computed at the islet level rather than at the single-cell level, 172 
the observed decreased expression of β cell markers could be due to a loss of β cells or to 173 
downregulation of β cell markers in β cells or both. To separate these phenomena, we first 174 
compared the islet β cell fractions at the three pseudostages. The proportion of β cells decreased 175 
only slightly from pseudostage 1 to pseudostage 2, whereas pseudostage 3 was essentially 176 
composed of pseudo-atrophic islets, i.e. which are devoid of β cells (Figure 3E). In addition, we 177 
examined how islet shape changed with pseudostage progression. Islet extent (islet area divided 178 
by islet bounding box) and solidity (proportion of pixels in the islet convex hull that are also in the 179 
islet), two metrics that reflect shape regularity, were similar for pseudostages 1 and 2 and 180 
decreased for pseudostage 3 (Figure 3F). This reflects altered islet shape at pseudostage 3, likely 181 
because of β cell destruction. 182 
We then examined how the expression of β cell markers evolved with pseudotime. We 183 
assessed the abundance of β cell markers in the β cells of each islet as a function of pseudotime. 184 
This approach revealed that expression of four β cell markers (INS, PIN, IAPP, and PTPRN) was 185 
strongly downregulated between pseudostages 1 and 2 but remained relatively stable between 186 
pseudostages 2 and 3 (Figure 3G and Figure S5A). By contrast, the expression of β cell 187 
transcription factors, PDX1 and NKX6-1, and pan-endocrine markers, SYP and CD99, did not 188 
vary substantially through the three pseudostages. Together, these results indicate that 189 
progression from pseudostage 1 to 2 is driven by a downregulation of β cell-specific markers, 190 
while progression to pseudostage 3 reflects β cell death. Similar results were obtained using 191 
Monocle2 (Qiu et al., 2017) instead of SCORPIUS for pseudotime analysis (Figure S5B-G), 192 
indicating that our results are independent of the pseudotime mapping algorithm used. We 193 
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performed similar analyses at the β cell level. Despite heterogeneity, β cells from non-diabetic 194 
controls and donors with T1D were largely separated by both hierarchical clustering and tSNE 195 
and had limited pseudotime overlap (Figure S5H-K). As in the islet-level analysis, this separation 196 
was mainly driven by a relative decrease in the abundance of INS, PIN, IAPP and PTPRN (Figure 197 
S5L). In summary, these findings indicate that islet evolution during T1D progression can be 198 
reconstructed from cross-sectional data and suggest that, at the islet level, alteration of the β cell 199 
phenotype precedes β cell destruction. 200 
 201 
Tc and Th Cells are Simultaneously Recruited to β Cell-Rich Islets at T1D Onset 202 
Autoimmunity is thought to be the driving force behind β cell death in T1D (Atkinson et al., 2014; 203 
Boldison and Wong, 2016). We therefore explored the evolution of immune cell composition 204 
through disease duration. We used supervised machine learning to identify the main immune cell 205 
types in our dataset: cytotoxic T cells (Tc, CD3+CD8+CD45RA-), naïve (possibly EMRA) Tc cells 206 
(naïve Tc, CD3+CD8+CD45RA+), helper T cells (Th, CD3+CD4+), B cells (CD20+), 207 
monocytes/macrophages (MΦ, CD45+CD68+), and neutrophils (Neutr., MPO+). In addition, 208 
remaining CD45+ or CD45RA+ cells, to which no specific cell type could be attributed, were 209 
classified as “other”. Overall, T cells were more abundant in donors with recent-onset T1D and 210 
the number of B cells was very low in most pancreata, except for one donor with recent-onset 211 
T1D (nPOD case 6228) (Figure 4A). We then measured the density of each immune cell type 212 
(i.e., number of cells per mm2) across T1D duration. All measured immune cell types were more 213 
abundant in recent-onset than in control donors (Figure 4B). In long-duration T1D donors, MΦ 214 
and neutrophil densities were elevated relative to donors without T1D, whereas Tc and Th cell 215 
abundances were decreased compared to recent-onset donors but remained higher than in 216 
donors without T1D (Figure 4B and S6A). We then tested whether immune cell densities in islets 217 
differed from those in the surrounding exocrine tissue. Strikingly, the density (cells per mm2) of 218 
immune cells was lower in islets than in the exocrine compartment for all immune cell types except 219 
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B cells at all disease stages (Figure 4C). Yet, while immune cell densities never exceeded 20 220 
cells per mm2 in the exocrine tissue, a few islets exhibited much higher values. Next, we 221 
investigated whether positions of immune cells relative to islets varied but did not observe an 222 
accumulation of immune cells at islet peripheries (Figure 4D). The exception to this was observed 223 
in a donor with recent-onset T1D (nPOD case 6414) with an accumulation of Tc and Th cells 224 
around the islet periphery (Figure S6B). Together, these results indicate that more immune cells 225 
are found in pancreata from donors with T1D than in non-diabetic controls. Most of these immune 226 
cells are not directly associated with islets, however. 227 
 To further explore interactions between islets and immune cells in T1D, we sought to 228 
correlate islet pseudostage information, which reflects the islet marker expression profile, with our 229 
immune cell data. We counted the number of immune cells associated with each islet (i.e., the 230 
number of immune cells located either inside the islet or within 20 μm of the islet rim) and 231 
calculated the fraction of islets with immune cell infiltration at different disease stages (Figure 4E 232 
and Figure S6C). Most islets from non-diabetic controls and donors with long-duration T1D had 233 
no or few associated immune cells. By contrast, around half of the islets from donors with recent-234 
onset T1D had six associated immune cells or more. Strikingly, insulitis (> 15 associated immune 235 
cells) was present in over 30% of β cell-rich (pseudostage 2) islets from recent-onset donors, but 236 
in less than 10% of β cell-depleted (pseudostage 3) islets from the same donors. We then 237 
examined how immune cell numbers varied with pseudostage progression. Islet-associated Tc 238 
and Th cells were more abundant in pseudostage 2 islets but these numbers decreased in 239 
pseudostage 3 islets from recent-onset T1D donors and further decreased in pseudostage 3 islets 240 
from donors with long-duration T1D, suggesting that T cells progressively leave islets after β cell 241 
destruction (Figure 4F). Together, these results indicated that the number of islet-associated T 242 
cells depends on both disease duration (recent-onset versus long-duration) and the islet profile 243 
(presence of surviving β cells). 244 
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 We observed that Tc and Th cell numbers followed similar trajectories through pseudotime 245 
(Figure 4G), suggesting that these cells are recruited simultaneously to individual islets in T1D. 246 
This was confirmed by the positive correlation between the numbers of Tc and Th cells associated 247 
with individual islets, in particular at pseudostage 2 (Figure 4H). These findings indicated that the 248 
immune-mediated attack on β cells involves both Tc and Th cells, is maximal around the time of 249 
T1D onset, and focuses on islets that retain a high proportion of β cells. Moreover, our results 250 
show that pseudotime analysis based on islet expression profiles can be meaningfully combined 251 
with immune cell data to recreate the dynamics of interactions between islets and immune cells 252 
through T1D duration. 253 
 254 
Neighborhood Analysis Reveals Dynamic Changes in Cell-Cell Interactions in T1D 255 
In health and disease, tissue function depends on interactions between different cell types. This 256 
is also the case in the pancreas: Normal islet function depends on paracrine interactions between 257 
islet cells, and T1D progression is determined by interactions between immune and β cells. 258 
Understanding how cell-cell interactions change from one disease stage to the other is, therefore, 259 
key to a better understanding of T1D. To systematically probe interactions between cell types, we 260 
performed a large-scale neighborhood analysis (Schapiro et al., 2017). We measured, for each 261 
image, significant association or avoidance according to spatial proximity of all cell type pairs in 262 
our dataset (Figure 5A). Hierarchical clustering of individual images based on cell-cell interactions 263 
revealed a clear separation between images containing pseudostage 3 islets and those containing 264 
islets at pseudostages 1 or 2. This separation was essentially caused by β cell destruction, as 265 
illustrated by the rarity of significant association between β cells and other cell types in images 266 
containing pseudostage 3 islets (Figure 5A, green rectangle). This result confirmed that islet 267 
structure is maintained between pseudostage 1 and pseudostage 2 islets but is altered in 268 
pseudostage 3 islets. We then focused specifically on islets and compared the frequency of 269 
interactions between cell types at each pseudostage (Figure 5B). As expected, we observed 270 
 13 
 
frequent association between islet cells (Figure 5B, green rectangles), but interactions involving 271 
β cells were strongly reduced or absent in pseudostage 3 islets, as a result of β cell loss. 272 
Association between immune cells was also frequent, in particular at pseudostages 2 and 3 273 
(Figure 5B, magenta rectangles). By contrast, islet and immune cells essentially remained 274 
isolated from each other at all disease stages, confirming our previous observation that immune 275 
cells are rarely found within islets. 276 
 Cytotoxic and helper T cells are thought to be directly involved in the destruction of β cells 277 
in T1D (Boldison and Wong, 2016). Yet, our global neighborhood analysis did not detect 278 
association between T cells and β cells, even in donors with recent-onset T1D, where the rate of 279 
β cell death and islet infiltration are maximal. We, therefore, sought to study specifically the 280 
evolution of interactions between β and T cells through disease progression. First, we counted 281 
how often β cells were associated with Tc, respectively Th cells. This number remained extremely 282 
low in all islets but was highest for β cells from pseudostage 2 islets, i.e. β cell-rich islets from 283 
donors with recent-onset T1D (Figure 5C). Conversely, T cells were more often associated with 284 
β cells located in pseudostage 2 islets (Figure 5D). Next, we calculated for each islet the fraction 285 
of β cells associated with either Tc or Th cells. Again, more islets displayed such contacts at 286 
pseudostage 2 (Figure 5E). Even in those islets, though, the percentage of β cells associated with 287 
T cells was rarely above 10%. Conversely, the fraction of T cells associated with β cells was also 288 
higher in pseudostage 2 islets (Figure 5F). The small fraction of β cells in contact with T cells 289 
likely explains why our global neighborhood analysis did not allow detecting those associations. 290 
Together with the results of our immune cell analysis, these results suggested that not only 291 
pseudostage 2 islets have more associated T cells, but also that, in those islets, T cells contact β 292 
cells more frequently. Nevertheless, the frequency of interactions between β and T cells remained 293 
very low at all disease stages.  294 
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DISCUSSION 295 
Here we used highly multiplexed imaging of human pancreas sections by IMC to generate a 296 
comprehensive map of T1D progression. Analysis of islet cell composition showed that two 297 
donors with recent-onset T1D had a proportion of β cells in islets similar to that observed in non-298 
diabetic controls (Figure 2B). The discrepancy with β cell fractions usually reported can be, at 299 
least in part, explained by the presence of insulin-negative β cells, which we detected by co-300 
expression of Pdx1 and Nkx6.1. These β cells with altered phenotypes are not detected when β 301 
cell identification relies exclusively on insulin (Rodriguez-Calvo et al., 2017; Wasserfall et al., 302 
2017). The question remains, however, how patients with such high numbers of remaining β cells 303 
develop clinical symptoms of T1D. We found that roughly half of the islets from donors with recent-304 
onset T1D retained a “normal” fraction of β cells with an unaltered islet structure (Figure 3E). The 305 
β cells in these islets, however, exhibited reduced expression of β cell markers as compared to β 306 
cells from healthy control islets (Figure 3G). This altered phenotype may be a consequence of 307 
stress and/or increased metabolic demand or, potentially, may allow escape from detection by 308 
the immune system (Rui et al., 2017). This finding is crucial from a therapeutic point of view 309 
because the presence of a high number of surviving β cells at T1D onset implies that if factors 310 
driving disease progression could be halted or slowed these cells might have the opportunity to 311 
regain functionality. 312 
Much of our knowledge regarding T1D pancreas pathology has resulted from analyses of 313 
sections collected from deceased pancreas donors, and the lack of sampling over the course of 314 
the disease has clearly hampered study of this disorder. We show here that performing 315 
pseudotime ordering at the islet level represents a powerful method to reconstruct time 316 
trajectories from snapshot data, and studies such as ours may overcome the sample limitation 317 
issues. In particular, we investigated the dynamics of immune cell recruitment around T1D-318 
affected islets and found that the number of islet-associated T cells depends on both disease 319 
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stage and islet profile. In addition, we observed simultaneous recruitment of Tc and Th cells to 320 
individual islets before β cell destruction in subjects already diagnosed with T1D. This result 321 
confirms that these cell types form a destructive immune motif that plays a pivotal role in β cell 322 
demise. Finally, our analyses indicate that immune cells are rarely in direct contact with islet cells. 323 
This could be explained by the fact that infiltrating immune cells are more often located at the islet 324 
periphery (peri-insulitis), than inside islets (intra-insulitis) (Pugliese, 2016). The position of β cells, 325 
which are rarely located in the outer islet layer (Figure 2E), may represent an additional barrier. 326 
Finally, the chronic nature of the disease, with β cell destruction taking place over long-time 327 
periods, is consistent with a model in which contacts between T and β cells are relatively short 328 
and infrequent, making their detection in fixed tissue sections difficult. 329 
For this first effort toward analysis of human pancreata using highly multiplexed imaging, 330 
we designed a broad antibody panel that enabled discrimination of the main pancreatic and 331 
immune cell types and selected cases that represented short and long duration T1D. We envision 332 
that future studies will attempt to address specific questions with tailored antibody panels and 333 
higher numbers of donors in order to increase the statistical power, to better capture heterogeneity 334 
among donors, and to explore other patient-related parameters known to influence T1D 335 
progression, such as age. A number of questions regarding T1D development remain open. We 336 
could not determine, for instance, whether recruitment of immune cells to pancreatic islets 337 
precedes or follows downregulation of insulin and other β cell markers. Because β cell phenotypes 338 
are already altered in recently diagnosed donors, determining the cause of this alteration and the 339 
underlying mechanisms will require studying samples from pre-diabetic subjects. 340 
The techniques and concepts described in the current study, together with the co-341 
submitted manuscript (Wang et al., 2018), will open new avenues for the exploration of T1D 342 
pancreas pathology and will help to address the crucial questions that still surround the disorder. 343 
Moreover, the approaches described herein should be applicable to the study of other diseases 344 
and will be especially valuable for deciphering complex cellular interactions.  345 
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 346 
Limitations of study 347 
Some limitations remain when IMC is used for analysis of pancreas tissues. First, all 348 
results are a function of the selected antibodies. Antibodies used in this study were thoroughly 349 
validated (STAR Methods). In IMC, antigens are most often directly detected with primary 350 
antibodies so options for signal amplification are limited. Moreover, due to the multiplexed nature 351 
of IMC, a single staining protocol must be used, whereas in IF or IHC the conditions can be 352 
optimized for each antibody. Conjugation can also affect the performance of some antibodies. 353 
New antibody conjugation methods will become available in the near future (Allo et al., 2018). 354 
Second, the area that can be imaged by IMC is constrained by acquisition speed. To overcome 355 
this caveat, we used IF to select areas of interest for IMC analysis. Yet, the number of slides that 356 
can be imaged remains limited. In this study, we have analyzed two sections per donor, but we 357 
have acquired a large number of islets per section, such that variations related to the sectioning 358 
plane should average out. In this regard, we note that islet cellular compositions were globally 359 
similar between sections from different anatomical regions of the same pancreas. Third, among 360 
the most challenging processes in multiplexed image analysis is cell segmentation. Because cell 361 
borders are not always clearly defined and because individual pixels may contain information from 362 
more than one cell (Schapiro et al., 2017), tissue imaging data are noisier than what is typically 363 
obtained with suspension analysis methods. We have, therefore, implemented supervised 364 
machine learning for cell type attribution to overcome this challenge. These computational 365 
pipelines and new tools to be developed in the future will lead to further improvements in the 366 
quality of IMC-generated data. 367 
  368 
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MAIN FIGURE LEGENDS 521 
Figure 1. Acquisition of Single-Cell and Islet Level Data by IMC 522 
A. IMC workflow. A laser ablates the tissue spot-by-spot, generating clouds of particles that are 523 
atomized and ionized in an inductively coupled plasma before analysis by mass cytometry. Based 524 
on ion cloud composition, an image of the ablated area is created for each measured marker. 525 
B. IMC images, here represented by a combination of proinsulin (magenta), glucagon (cyan), and 526 
somatostatin (yellow) (top), were segmented into cells. The cell mask is shown as a white overlay 527 
(bottom). 528 
C. Marker expression was measured by applying cell masks onto IMC images (left). Protein 529 
abundance in single cells can be visualized using tSNE (right). 530 
D. Imaged cells were classified into cell types (left). Cells were first divided into four categories: 531 
islet (red), exocrine (blue), immune (green), and “other” (yellow) (left). Each category was then 532 
subdivided into cell types. Islet cells were classified as α (cyan), β (magenta), δ (yellow), or γ (red) 533 
cells (center). This allowed determination of islet cellular composition (right). 534 
E. Cell masks enabled retrieval of spatial data, such as cell area (left). Neighborhood information 535 
(center) was used to systematically analyze cell-cell interactions (right). 536 
F. The expression of endocrine cell markers, such as synaptophysin (red) (top), was used to 537 
identify islets and generate islet masks (white overlay, bottom). 538 
G. By combining cell and islet masks, each cell was related to the islet to which it belongs (left). 539 
The distance of cells to the islet rim was also measured (center), allowing comparison of cell 540 
positions relative to islets (right). 541 
H. Spatial information (left) and protein abundance (center) were measured at the islet level using 542 
islet masks. Islet level data were used to perform pseudotime analyses (right). 543 
Scale bars: 100 μm. 544 
 545 
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Figure 2. IMC Exploration of Islet Heterogeneity 546 
A. Cell type composition of the 1581 islets (≥ 10 islet cells) captured in our dataset. Each stacked 547 
bar represents a single islet with colors indicating β (red, n = 56,594), α (light red, n = 101,592), 548 
δ (blue, n = 18,833), and γ (light blue, n = 3721) cells. 549 
B. Average islet cell type fraction for each of the 12 donors in our dataset. 550 
C. Average islet cell type fraction per pancreas section. The region of origin of each section is 551 
indicated on the x-axis. Significant P values for comparison of β cell fractions between sections 552 
of the same pancreas are indicated. 553 
D. Average islet cell type fraction versus islet size. For each bin size, β cell fraction was compared 554 
to the average β cell fraction for the central bin (35-100 cells). 555 
E. Islet cell type fractions as a function of distance to islet rim. Cell types β (red, n = 39,557), α 556 
(light red, n = 73,174), δ (blue, n = 14,396), γ (light blue, n = 3431) cells. Bin sizes, 5 μm. The 557 
leftmost bin represents cells located within 5 μm of the islet rim and increasing bin numbers 558 
indicate cells located closer and closer to the islet center. 559 
F. Islet cell type fractions as a function of distance to blood vessels. Cell types: β (red, n = 42,948), 560 
α (light red, n = 89,782), δ (blue, n = 16,114), γ (light blue, n = 2734) cells. Bin sizes, 5 μm. The 561 
leftmost bin represents cells located within 5 μm of the blood vessel, and increasing bin numbers 562 
represent cells located farther and farther away. 563 
*, P < 0.01; **, P < 0.001; ***, P < 0.0001 for β cell fractions; †, P < 0.01; ††, P < 0.001; †††, P < 564 
0.0001 for α cell fractions (Mann-Whitney U test with Holm adjustment). Error bars, SEM. 565 
 566 
Figure 3. Evolution of Islet Profiles with T1D Progression 567 
A. tSNE map representing the expression profiles of 1494 islets (≥ 15 cells) from 12 donors at 568 
different stages of T1D (one circle = one islet, 90 to 155 islets per donor, see also Figure S4B). 569 
The dotted blue circle indicates a cluster composed of islets from donors with different disease 570 
durations. 571 
 24 
 
B. Pseudotime analysis of islet expression profiles using SCORPIUS. Islets, represented by 572 
circles, were first projected into a two-dimensional space (Components 1 and 2). A trajectory, 573 
represented by the black curve, was then inferred in the reduced space. Pseudotime was 574 
measured by projecting the islets onto the trajectory (see also Figure S4C-D). 575 
C. Heatmap showing expression of islet markers with columns representing islets arranged 576 
according to pseudotime progression. 577 
D. Violin plots showing islet distribution over pseudotime for the three disease stages (left). 578 
Pseudostages are indicated in blue and are defined based on the density distribution of islets for 579 
each disease stage (right). The percentage of islets in each stage and pseudostage is indicated 580 
in blue. Horizontal blue lines, defined by the intersections of islet density distributions, indicate 581 
pseudostage separations (see also Figure S4E). 582 
E. Islet β cell fraction for each pseudostage. Pseudostage 1, n = 514 islets; pseudostage 2, n = 583 
289 islets; pseudostage 3, n = 691 islets. 584 
F. Islet extent and solidity measured for each pseudostage. For both metrics, a decrease indicates 585 
a more concave or irregular shape. 586 
G. Evolution of β cell marker expression in β cells through pseudostages. Expression levels were 587 
measured in single β cells and averaged for each islet (see also Figure S5A). Pseudostage 1, n 588 
= 38,479 β cells from 514 islets; pseudostage 2, n = 16,103 β cells from 289 islets; pseudostage 589 
3, n = 618 β cells from 691 islets. 590 
Pairwise comparisons of the three pseudostages: *, P < 0.01; **, P < 0.001; ***, P < 0.0001, n.s., 591 
not significant (Mann-Whitney U test with Holm adjustment). 592 
 593 
Figure 4. Dynamics of Immune Cell Recruitment during T1D Progression 594 
A. Distribution of immune cell types per donor and T1D stage. Number of cells analyzed: Tc, 595 
15,367; Naïve Tc, 890; Th, 5417; B, 869; MΦ, 16,021; Neutr., 20,800; Other, 10,299. 596 
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B. Density (cells per mm2) of immune cell types in pancreata from controls and donors with T1D 597 
(see also Figure S6A). P values, pairwise comparisons of T1D stages. 598 
C. Immune cell densities inside islets (green lining) and in the exocrine tissue (blue lining) in 599 
controls and donors with T1D. P values, comparison of densities in islets versus exocrine tissue. 600 
D. Average number of immune cells over binned distance to islet rim (see also Figure S6B). Bin 601 
size, 10 μm. Negative and positive values represent bins located outside and inside islets, 602 
respectively. The dotted vertical lines indicate the islet rim. B cells were not numerous enough to 603 
be meaningfully plotted. Error bars, SEM. 604 
E. Fraction of islets containing given numbers of associated immune cells (inside the islet or within 605 
20 μm of the islet rim), in function of pseudostage (see also Figure S6C). 606 
F. Number of immune cells associated with islets at different pseudostages. Number of cells 607 
analyzed: Tc, 3533; Naïve Tc, 264; Th, 1309; B, 165; MΦ, 1915; Neutr., 2234; Other, 1868. P 608 
values, comparison of immune cell numbers for consecutive pseudostages. 609 
G. Number of Tc (red) and Th (blue) cells associated with individual islets plotted versus islet 610 
pseudotime. Curves: smoothed conditional means (local polynomial regression fitting), grey 611 
areas: 95% confidence intervals. 612 
H. Number of Tc and Th cells per islet at different pseudostages. Pearson correlations are 613 
indicated, P values were < 1e-12 for the four pseudostages. 614 
*, P < 0.01; **, P < 0.001; ***, P < 0.0001, n.s., not significant (Mann-Whitney U test with Holm 615 
adjustment). 616 
 617 
Figure 5. Neighborhood Analysis Reveals Dynamic Changes in Cell-Cell Interactions in 618 
T1D 619 
A. Heatmap showing interactions between all cell type pairs (columns) for each individual image 620 
in our dataset (rows). Colors indicate significant (P < 0.01) cell type association (red) or avoidance 621 
(blue). Rows are ordered by hierarchical clustering. Non-present and non-significant interactions 622 
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are indicated in white. The green rectangle highlights interactions between β cells and other cell 623 
types in images containing pseudostage 3 islets. 624 
B. Frequency of cell-cell interactions in islets and in the 20 μm surrounding area for each 625 
pseudostage. Colors indicate the percentage of donors that display significant association (red) 626 
or avoidance (blue) between two cell types. Green rectangles indicate interactions between islet 627 
cells and magenta rectangles indicate interactions between immune cells. 628 
C. Average number of interactions per β cell, with either Tc or Th cells, averaged by islet. Only 629 
islets containing at least one β cell were considered. 630 
D. Average number of interactions per Tc or Th cell with β cells, averaged by islet. Only islets with 631 
at least one associated T cell were considered. 632 
E. Fraction of islets showing association between β and T cells, in function of the percentage of 633 
β cells associated with T cells. 634 
F. Fraction of islets showing association between T and β cells, in function of the percentage of 635 
T cells associated with β cells. 636 
*, P < 0.01; **, P < 0.001; ***, P < 0.0001, n.s., not significant (Mann-Whitney U test with Holm 637 
adjustment).  638 
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MAIN TABLES 639 
Compartment Short name Antigen Main target cells Metal tag 
 INS Insulin β 141Pr 
 PIN Proinsulin β 154Sm 
 GCG Glucagon α 156Gd 
 SST Somatostatin δ 159Tb 
 PPY Pancreatic polypeptide γ 153Eu 
 NKX6-1 Nkx6.1 β 169Tm 
 PDX1 Pdx1 β, δ, ductal 158Gd 
Pancreas IAPP Amylin β 167Er 
 PCSK2 Proprotein convertase 2 α 144Nd 
 SYP Synaptophysin Endocrine 160Gd 
 CD99 CD99 Endocrine 145Nd 
 SLC2A1 Glucose transporter 1 Endocrine 148Nd 
 PTPRN 
Receptor-type tyrosine-protein 
phosphatase-like N 
Endocrine 174Yb 
 AMY2A Pancreatic amylase Acinar 150Nd 
 KRT19 Cytokeratin 19 Ductal 161Dy 
 CD44 CD44 Exocrine 143Nd 
 CD45 CD45 Immune 162Dy 
 CD45RA CD45RA Immune 164Dy 
 CD3e CD3ε T 152Sm 
 CD4 CD4 Helper T 171Yb 
Immune CD8a CD8a Cytotoxic T 165Ho 
 CD20 CD20 B 149Sm 
 CD68 CD68 
Monocytes, 
macrophages 
146Nd 
 MPO Myeloperoxidase Neutrophils 147Sm 
 FOXP3 Forkhead box P3 Regulatory T 163Dy 
 CD38 CD38 Immune 142Nd 
 CDH E-/P-cadherin Epithelial 173Yb 
 CD31 CD31 Endothelial 172Yb 
 SMA Smooth muscle actin Stromal 115In 
 KI-67 Ki-67 Proliferating 168Er 
 pH3 Phospho-histone H3 Proliferating 170Er 
Misc pRB1 Phospho-retinoblastoma Cycling 175Yb 
 cPARP1 
Cleaved caspase 3 
+ poly (ADP-ribose) polymerase 
Apoptotic 176Yb 
 CA9 Carbonic anhydrase IX Hypoxic 166Er 
 H3 Histone H3 Nuclei 113In 
 Ir191, Ir193 (DNA intercalators) DNA 191Ir, 193Ir 
Table 1. Imaging Mass Cytometry Panel  640 
 28 
 
STAR METHODS 641 
CONTACT FOR REAGENT AND RESOURCE SHARING 642 
Further information and requests for resources and reagents should be directed to and will be 643 
fulfilled by the Lead Contact, Bernd Bodenmiller (bernd.bodenmiller@imls.uzh.ch). 644 
 645 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 646 
Human Organ Donors 647 
Pancreas samples were obtained from nPOD (www.jdrfnpod.org). All procedures were approved 648 
by the University of Florida Institutional Review Board (IRB201600029) and the Zurich Cantonal 649 
Ethics Committee (2017-02302). Procedures were also approved by the United Network for 650 
Organ Sharing (UNOS) according to federal guidelines, and informed consent was obtained from 651 
each donor’s legal representative. For each donor, a medical chart review was performed and C-652 
peptide measured (Campbell-Thompson et al., 2012a) with T1D diagnosis determined or 653 
confirmed according to the ADA guidelines. Demographics, length of hospitalization, and organ 654 
transport duration information was obtained from hospital records or UNOS. Donor pancreata 655 
were recovered, shipped in transport media on ice via organ courier to the University of Florida, 656 
and processed by a licensed pathology assistant (Campbell-Thompson et al., 2012b). The cases 657 
were selected to represent recent onset T1D (< 0.5 years), long-standing T1D (≥ 8 years), and 658 
non-diabetes control. Four groups of three donors with different disease duration but matched by 659 
age and gender were analyzed. Additional donor information is listed in Table S1. 660 
 661 
METHOD DETAILS 662 
Antibody Testing and Validation 663 
All antibodies in the panel (Table 1) were initially tested by IF on lymphoid tissues (spleen, tonsil, 664 
and lymph node) for antibodies targeting immune markers and on pancreas for the other markers. 665 
 29 
 
Only antibodies that produced expression patterns consistent with the literature and a high signal 666 
intensity were conjugated to metals. After metal labeling, all antibodies were tested again by IMC 667 
to ensure that antibody specificity was not affected by conjugation. Finally, the entire antibody 668 
panel was used to stain two tissue arrays: an array containing large cores from six different tissues 669 
and a microarray containing 78 cores representing 20 different tissues from healthy subjects and 670 
cancer patients. In this way, each antibody could be positively validated on tissues known to 671 
express the target antigen and negatively validated on tissues known to be negative for that 672 
antigen. The main observations used to validate each antibody are listed in Table S2. 673 
 674 
Antibody Conjugation and Titration 675 
Antibodies were conjugated to metals using the MaxPar X8 Multimetal Labeling Kit (Fluidigm) 676 
according to the manufacturer’s protocol. To determine optimal antibody concentrations, the 677 
antibody panel was divided in “odd” and “even” channels, depending on the atomic mass of the 678 
metal tag, and two-fold serial antibody dilutions were performed. Sections of human pancreas 679 
and lymphoid tissue (spleen, tonsil, pancreatic lymph node) were divided in four areas, and each 680 
area was stained with a different antibody dilution. Separate slides were used for antibodies 681 
conjugated to odd and even metal isotopes. After IMC measurement, each channel was examined 682 
visually and the dilution that produced the highest signal-to-noise ratio was selected. In the few 683 
cases where notable spillover was detected in the adjacent (+1 and -1) channels, a higher 684 
antibody dilution was selected. 685 
 686 
Tissue Staining 687 
Two sections per pancreas, from head, body, or tail, were stained with our full antibody panel 688 
(Table 1). Slides were incubated for 1 h at 60 °C in a dry oven, deparaffinized in fresh Xylol, and 689 
rehydrated through a graded alcohol series. Antigen retrieval was performed in a decloaking 690 
chamber (Medite) for 30 min at 96 °C in Tris-EDTA, pH 9.2. After blocking in buffer containing 691 
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10% normal horse serum, slides were incubated overnight at 4 °C with three primary antibodies: 692 
rabbit anti-glucagon-156Gd, rabbit anti-synaptophysin-160Gd, and goat anti-Pdx1 (unconjugated). 693 
The next day, slides were incubated with anti-rabbit IgG-Alexa Fluor 488 and anti-Goat IgG-158Gd 694 
secondary antibodies for 1 h at room temperature, followed by Hoechst dye counterstaining (5 695 
min at room temperature). Slide scanner imaging was performed at this stage (see Selection of 696 
Areas of Interest below). Two successive overnight incubations at 4 °C were then performed for 697 
labeling with the remainder of primary antibodies (13 primary antibodies on the first night and 19 698 
on the second night). Finally, slides were counterstained with iridium intercalator for 5 min at room 699 
temperature, quickly dipped in doubly distilled H2O, and immediately dried with pressurized air. 700 
 701 
Selection of Areas of Interest 702 
Pancreas sections stained for glucagon and synaptophysin and counterstained with Hoechst were 703 
imaged with a slide scanner (Zeiss Axio Scan.Z1) at 20X magnification. Areas of interest were 704 
chosen manually based on islet size (islets representing the complete spectrum of size observed 705 
but with an enrichment for large islets) and islet position (to ensure distribution of sampling over 706 
the whole section) (Figure S1A). Area size was defined as the axis-aligned minimum bounding 707 
box containing all islets in the area, expanded by 100 μm in all directions. The coordinates of 708 
areas of interest were recorded using ImageJ and transformed to IMC coordinates using a custom 709 
Python script (see Key Resources Table). 710 
 711 
IMC Image Acquisition 712 
Data acquisition was performed on a Helios time-of-flight mass cytometer (CyTOF) coupled to a 713 
Hyperion Imaging System (Fluidigm). Prior to laser ablation, optical images of slides were 714 
acquired using the Hyperion software, and the areas to ablate were selected as described above. 715 
Laser ablation was performed at a resolution of approximately 1 μm and a frequency of 200 Hz. 716 
Slides were acquired in a randomized order over 25 consecutive days. To ensure performance 717 
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stability, the machine was calibrated daily with a tuning slide spiked with five metal elements 718 
(Fluidigm). In total, 851 image stacks from 24 pancreas sections were acquired. Three were 719 
removed due to data corruption, one due to poor image quality, and two because the areas did 720 
not contain any islets. All analyses were performed on the 845 remaining image stacks. 721 
 722 
QUANTIFICATION AND STATISTICAL ANALYSIS 723 
IMC Data Preprocessing 724 
Text format (.txt) files generated during data acquisition were converted to tiff images using a 725 
custom Python script (https://github.com/BodenmillerGroup/imctools). For visualization, false 726 
color images were prepared from tiff images using Fiji (https://fiji.sc). 727 
 728 
Spillover Compensation 729 
Although spectral overlap between pure metal isotopes is very limited, channel crosstalk caused 730 
by isotopic impurity, oxide formation, and imprecision in ion detection still exist (Chevrier et al., 731 
2018). To measure crosstalk from one channel to the other, we generated a slide spotted with the 732 
same metals used for antibody conjugation (one metal isotope per spot). With this strategy, each 733 
metal can be measured individually while having all channels open for detection, thus allowing for 734 
spillover quantification across all measured channels. The slide was measured three times during 735 
the 25 days of IMC data acquisition, and an average spillover matrix was generated from the 736 
resulting data (Figure S1B). This matrix was used to correct for spillover in our dataset (Figure 737 
S1C), as described (Chevrier et al., 2018). 738 
 739 
Image Segmentation 740 
We generated cell segmentation masks in two steps: First, we used the interactive machine 741 
learning software ilastik to classify pixels as nucleus, cytoplasm/membrane, and background 742 
compartments. Second, we imported the probability maps generated by ilastik into CellProfiler to 743 
 32 
 
identify individual nuclei, define cell borders, and generate cell masks. We adopted a similar 744 
approach to segment islets (Figure S3). 745 
 746 
Pixel Classification 747 
For cell segmentation, the pixels in each image were defined as belonging to the nucleus, 748 
cytoplasm, or background compartment using the pixel classification module of the open source 749 
software ilastik (Sommer et al., 2011) as described (Schulz et al., 2018) 750 
(https://github.com/BodenmillerGroup/ImcSegmentationPipeline). Training of the Random Forest 751 
classifier was performed on 125 x 125 pixels substacks generated from the original images and 752 
containing only informative markers (i.e., H3, CDH, CD99, CD44, MPO, SYP, KRT19, CD45, 753 
CD31, SMA, and Iridium). This allowed for the generation of maps that integrate for each pixel 754 
the probability of belonging to each of three compartments, as shown in Figure 1B (center). Based 755 
on the trained classifier, probability maps were generated for the whole dataset and exported as 756 
tiff files in batch mode. 757 
 758 
Cell Segmentation 759 
CellProfiler (Kamentsky et al., 2011) was subsequently used to define cell masks and quantify 760 
marker expression. To define cell borders, nuclei were first identified as primary objects based on 761 
ilastik probability maps and expanded through the cytoplasm compartment until either a 762 
neighboring cell or the background compartment was reached. Cell masks were generated for 763 
identification of single cells and used to extract single-cell information (marker abundance, spatial 764 
and neighborhood data) from the original images. The results were exported as csv tables for 765 
further analysis. 766 
 33 
 
 767 
Islet and Blood Vessel Segmentation 768 
Islet and blood vessel segmentation was performed in a similar manner as cell segmentation with 769 
the following modifications: i) for ilastik pixel classification, images were divided into islet, blood 770 
vessels, and “other” (that is non-islet, non-vessel) compartments based on substacks containing 771 
informative markers (i.e., SYP, CD99, CD31, CD45, AMY2A, KRT19, and Iridium); ii) in 772 
CellProfiler, islets and blood vessels were directly defined as primary objects. Distance to islet rim 773 
was measured by combining islet and cell masks, using a custom CellProfiler plugin 774 
(https://github.com/BodenmillerGroup/ImcPluginsCP).  775 
 776 
Cell Type Definition 777 
The object classification module of ilastik was used to define cell types (Figure S3). First, binary 778 
cell masks and substacks containing relevant markers (i.e., CD99, SYP, AMY2A, KRT19, CD44, 779 
CDH, CD45, CD3, CD8, CD20, MPO, CD68, and SMA) were loaded into ilastik and a classifier 780 
was trained in order to divide the cells in four main categories (islet, immune, exocrine, and 781 
“other”). The resulting object predictions were exported as tiff images and imported into 782 
CellProfiler to generate cell masks specific to each cell category. The process was iterated to 783 
subdivide each category into cell types. For islet cell type definition, masks containing only cells 784 
defined in the first step as belonging to the islet category were imported into ilastik, and a new 785 
training was performed to attribute α, β, δ, and γ cell types based on the expression of islet-786 
expressed markers (i.e., INS, PIN, GCG, SST, PPY, PDX1, NKX6-1, IAPP, PCSK2, CD99, and 787 
SYP). The same approach was adopted to define B cells, cytotoxic and helper T cells, 788 
monocytes/macrophages, and neutrophils among immune cells (markers used: CD45, CD3e, 789 
CD4, CD8a, CD20, CD68, MPO, and CD45RA). In addition, exocrine cells were divided into 790 
acinar and ductal cells (markers used: KRT19, AMY2A, CD44, and CDH), and “other” cells were 791 
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divided into three cell types: endothelial (also includes peri-endothelial cells), stromal, and 792 
unknown (markers used: SMA, CD31, CD68, and CDH). 793 
 794 
Pseudotime Analysis 795 
Pseudotime analysis was performed using the trajectory inference algorithm SCORPIUS 796 
(Cannoodt et al., 2016), and results were confirmed using the Monocle2 DDRTree algorithm (Qiu 797 
et al., 2017). Only islets containing 15 cells or more were considered. Islet expression profiles 798 
and pseudotime ordering were based on the expression of islet-expressed markers averaged 799 
over the islet sectional area. All measured islet markers were considered (INS, PIN, GCG, SST, 800 
PDX1, NKX6-1, IAPP, PCSK2, SLC2A1, PTPRN, SYP, and CD99), except for PPY. The presence 801 
of a γ cell-rich pancreas head section in one donor with long-duration T1D tended to confound 802 
the algorithms, resulting in classification of the very few γ cell-rich islets from non-diabetic donors 803 
into the long-duration (pseudostage 3) category. Raw IMC counts averaged over islet areas were 804 
used as an input. 805 
 806 
Neighborhood Analysis 807 
Neighborhood analysis was performed using R and histoCAT (Schapiro et al., 2017). Custom 808 
scripts were used to import cell type and pseudotime information into histoCAT (see Key 809 
Resources Table). An expansion of 3 pixels was used to detect cell neighbors. The presence of 810 
significant cell type association or avoidance was determined using 999 random permutations of 811 
cell type labels and a significance threshold of P < 0.01. All other parameters and methods were 812 
chosen as suggested in the original publication (Schapiro et al., 2017). 813 
 814 
Data Analysis 815 
Data were analyzed and graphed using R and histoCAT (Schapiro et al., 2017). In particular, an 816 
R implementation of tSNE (https://cran.r-project.org/web/packages/tsne) was used to generate 817 
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tSNE maps (van der Maaten and Hinton, 2008). Unless otherwise stated, raw IMC counts were 818 
99th-percentile-normalized and scaled from 0 to 1 (scaled counts). 819 
 820 
Statistics 821 
Statistical tests were performed using R. Statistical parameters are reported in the figure legends. 822 
For pairwise group comparisons, we systematically used a non-parametric statistical test 823 
(unpaired, two-tailed Mann-Whitney U test) and applied the Holm post-hoc adjustment method to 824 
correct for multiple comparisons. Overall, the P value significance threshold was defined as 0.01. 825 
In text and figures, N represents the number of donors and n represents either the number of cells 826 
or the number of islets (as indicated in figure legends). In histograms, bars represent the means 827 
and error bars represent standard errors of the mean. Correlation analyses in Figure 4H were 828 
performed using Pearson’s r correlation coefficient. As mentioned above (see the IMC Image 829 
Acquisition paragraph), six out of 851 IMC images were excluded because of data corruption, 830 
poor image quality, or absence of islets. No other data or values were excluded from our analyses. 831 
 832 
DATA AND SOFTWARE ABILITY 833 
Raw IMC data (including image stacks, single-cell data and islet-level data) are available from 834 
Mendeley Data (http://dx.doi.org/10.17632/cydmwsfztj.1). Custom code generated by the 835 
Bodenmiller lab for IMC data preprocessing and image segmentation is available online 836 
(https://github.com/BodenmillerGroup); histoCAT can be downloaded as a standalone application 837 
from the project page (https://github.com/BodenmillerGroup/histoCAT). Scripts for IF-to-IMC 838 
coordinate transformation, as well as code related to neighborhood analysis (cell type and 839 
pseudotime import and custom clustering) are available from Mendeley data 840 
(http://dx.doi.org/10.17632/cydmwsfztj.1). 841 
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KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Mouse monoclonal anti-Alpha smooth 
muscle actin 
Abcam Cat#ab76549, RRID:AB_2223019 
Goat polyclonal anti-Carbonic anhydrase 
IX 
R and D Systems Cat#AF2188, RRID:AB_416562 
Rabbit monoclonal anti-Caspase 3 BD Biosciences Cat#559565, RRID:AB_397274 
Rabbit monoclonal anti-CD3ε Cell Signaling Technology Cat#85061, RRID:AB_2721019 
Goat polyclonal anti-CD4 R and D Systems Cat#AF-379-NA, RRID:AB_354469 
Mouse monoclonal anti-CD8a Thermo Fisher Scientific Cat#14-0085-82, RRID:AB_11150240 
Mouse monoclonal anti-CD20 Thermo Fisher Scientific Cat#14-0202-82, RRID:AB_10734340 
Mouse monoclonal anti-CD31 Novus Cat#NB600-562, RRID:AB_10002476 
Rabbit monoclonal anti-CD38 Abcam Cat#ab108403; RRID: AB_10890803 
Rat monoclonal anti-CD44 BD Biosciences Cat#550538, RRID:AB_393732 
Mouse monoclonal anti-CD45 Thermo Fisher Scientific Cat#14-9457-82, RRID:AB_11063696 
Mouse monoclonal anti-CD45RA BioLegend Cat#304102, RRID:AB_314406 
Mouse monoclonal anti-CD68 Thermo Fisher Scientific Cat#14-0688-82, RRID:AB_11151139 
Mouse monoclonal anti-CD99 BioLegend Cat#318002, RRID:AB_604112 
Mouse monoclonal anti-E-Cadherin BD Biosciences Cat#610182, RRID:AB_397581 
Rabbit monoclonal anti-Keratin 19 Cell Signaling Technology Cat#13092, RRID:AB_2722626 
Mouse monoclonal anti-Foxp3 Thermo Fisher Scientific Cat#14-4777-80, RRID:AB_467555 
Rabbit monoclonal anti-Glucagon Cell Signaling Technology Cat#8233, RRID:AB_10859908 
Rabbit monoclonal anti-Glucose 
Transporter 1 
Abcam Cat#ab115730, RRID:AB_10903230 
Donkey polyclonal anti-Goat IgG Thermo Fisher Scientific Cat#PA1-28659, RRID:AB_10981355 
Rabbit monoclonal anti-Histone H3 Cell Signaling Technology Cat#4499, RRID:AB_10544537 
Rat monoclonal anti-Histone H3 Phospho 
(Ser28) 
BioLegend Cat#641002, RRID:AB_1227659 
Rabbit monoclonal anti-Insulin Cell Signaling Technology Cat#3014, RRID:AB_2126503) 
Rabbit polyclonal anti-IAPP Atlas Antibodies Cat#HPA053194, RRID:AB_2682076 
Mouse monoclonal anti-Ki-67 BD Biosciences Cat#556003, RRID:AB_396287 
Rabbit polyclonal anti-Myeloperoxidase Dako Cat#A0398, RRID:AB_2335676 
Rabbit monoclonal anti-Nkx6.1 Cell Signaling Technology Cat#54551, RRID:AB_2722625 
Rabbit polyclonal anti-Pancreatic 
Amylase 
Abcam Cat#ab21156, RRID:AB_446061 
Mouse-monoclonal anti-Pancreatic 
Polypeptide 
R and D Systems Cat#MAB62971, RRID:AB_11127208 
Mouse monoclonal anti-cleaved PARP 
(Poly [ADP-Ribose] Polymerase) 
BD Biosciences Cat#552597, RRID:AB_394438 
Goat polyclonal anti Pdx1 R and D Systems Cat#AF2419, RRID:AB_355257 
Mouse monoclonal anti-Proinsulin Abcam Cat#ab8301, RRID:AB_306453 
Rabbit polyclonal anti-Prohormone 
Convertase 2 
Merck Cat#AB15601-I, RRID:AB_2722624 
Rabbit polyclonal anti-PTPRN Sigma-Aldrich Cat#HPA007179, RRID:AB_1079714 
Rabbit polyclonal anti-phospho Rb 
(Ser807/811) 
Cell Signaling Technology Cat#9308, RRID:AB_331472 
Rabbit polyclonal anti-Somatostatin Dako Cat#A0566, RRID:AB_10013726 
Rabbit monoclonal Synaptophysin Abcam Cat#ab32127, RRID:AB_2286949 
Key Resource Table
  
Donkey polyclonal anti-rabbit IgG, Alexa 
Fluor 488 
Thermo Fisher Scientific Cat#A-21206, RRID:AB_2535792 
Biological Samples    
Human pancreas sections 
nPOD, University of Florida, 
Gainesville, FL 32610-0275 
https://www.jdrfnpod.org  
Chemicals, Peptides, and Recombinant Proteins 
Hoechst Sigma Aldrich Cat #94403-1ML 
Iridium intercalator Fluidigm Cat #201192B 
Critical Commercial Assays 
MaxPar X8 Multimetal Labeling Kit Fluidigm Cat# 201300 
Deposited Data 
IMC images This paper http://dx.doi.org/10.17632/cydmwsfztj.1  
Software and Algorithms 
CellProfiler 2.2.0 (Kamentsky et al., 2011) http://cellprofiler.org 
Fiji (ImageJ 1.51u) (Schindelin et al., 2012) https://fiji.sc  
histoCAT 1.73 (Schapiro et al., 2017) 
https://github.com/BodenmillerGroup/hi
stoCAT/releases  
Ilastik 1.2.2 (Sommer et al., 2011) http://ilastik.org  
Python 3.4.3 Python Software Foundation https://www.python.org  
R 3.4.1 R Development Core Team https://www.r-project.org  
Tools for IMC data processing Bodenmiller lab 
https://github.com/BodenmillerGroup/im
ctools  
IMC data segmentation pipeline Bodenmiller lab 
https://github.com/BodenmillerGroup/Im
cSegmentationPipeline  
Custom CellProfiler plugins Bodenmiller lab 
https://github.com/BodenmillerGroup/Im
cPluginsCP  
Code and guidelines for spillover 
compensation 
Bodenmiller lab 
https://github.com/BodenmillerGroup/cy
TOFcompensation 
IF-to-IMC coordinate transformation This paper http://dx.doi.org/10.17632/cydmwsfztj.1  
Code related to neighborhood analysis This paper http://dx.doi.org/10.17632/cydmwsfztj.1  
SCORPIUS 1.0 (Cannoodt et al., 2016) 
https://github.com/rcannood/SCORPIU
S  
Monocle2 (Qiu et al., 2017) 
http://cole-trapnell-
lab.github.io/monocle-release/docs  
R implementation of tSNE Justin Donaldson 
https://cran.r-
project.org/web/packages/tsne  
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Supplemental Figures and Tables
Figure S1. Selection of Areas of Interest and Spillover Compensation. Related to STAR Methods 
A. Slide-scanner immunofluorescence (IF) image of a pancreas section (tail from nPOD case 6278) stained for 
synaptophysin and glucagon (green) and counterstained with Hoechst (blue). White boxes indicate areas selected for 
analysis by IMC. The area indicated by a red box is shown at higher magnification on the right (top) and the same 
area imaged by IMC is shown below (bottom right). Channels shown on the IMC picture are glucagon plus 
synaptophysin (green) and iridium (Ir193, blue). Scale bars, 2000 μm (left), 100 μm (right). 
B. Spillover matrix generated from single isotope measurements. Values represent the percentage of signal from the 
row channels observed in the column channels. The red arrow indicates spillover from channel 113In into channel 115In. 
C. Images illustrating compensation of spillover from channel 113In into channel 115In. The white boxes highlight 
bright nuclei observed in the Histone H3 channel (top). The signal spills into the SMA channel (middle). After 
compensation, the spillover is removed from the SMA channel (bottom). 
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Figure S2. Human Pancreas Imaging by IMC. Related to Figure 1 
A. Representative images of the islet markers in our dataset. Relevant marker combinations are shown in color. Images 
are from a non-diabetic donor (nPOD case 6134). 
B. Representative images of the immune markers in our dataset (grayscale images). Relevant marker combinations 
are shown in color. Images are from a donor with recent-onset T1D (nPOD case 6380). Insets show higher 
magnification of the white boxes indicated in individual marker images. The white arrow indicates a CD4+FOXP3+ 
cell. 
C. Representative images of the other markers in our dataset (grayscale images). Relevant marker combinations are 
shown in color. Images are from a non-diabetic donor (nPOD case 6126). 
Scale bars: 50 μm. 
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Figure S3. Pipeline for IMC Data Processing (legend on next page)
Figure S3. Pipeline for IMC Data Processing. Related to STAR Methods 
Based on the expression of relevant markers, IMC images are segmented into individual islets and cells (left). For islet 
segmentation, a Random Forest classifier is trained in ilastik, and each pixel is attributed to the islet (red), blood vessel 
(green), or “other” (blue) compartment. This yields a probability map that allows generation of islet and blood vessel 
masks in CellProfiler, which are then used to extract islet-level data. For cell segmentation, each pixel is classified 
into the nucleus (red), cytoplasm/membrane (green), or background (blue) compartment in ilastik. CellProfiler first 
identifies individual nuclei from ilastik probability maps and then expands these nuclei to find cell borders. Finally, 
cell masks are used to extract cell-level information and are combined with islet masks to extract additional spatial 
information (e.g., distance to islet rim). Attribution of cell types to all segmented cells is performed in two steps. First, 
cells are classified into four categories in ilastik (islet, immune, exocrine, other) based on the expression of relevant 
markers. The resulting prediction masks are then used to perform cell type attribution within each cell category. For 
instance, cells belonging to the “islet” category are attributed to the α, β, δ, or γ cell type (right). Immune cell types 
are defined in the same fashion and cell types are extracted from ilastik predictions using CellProfiler. Insets in the 
second column show higher magnification. Scale bars: 100 μm. 
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Figure S4. Islet-Level Analysis. Related to Figure 3. 
A. Hierarchical clustering of pancreas donors based on the expression of islet markers measured at the islet level 
(protein abundance averaged over the islet surface). The disease stage of each donor is color-coded on the left. n = 
1494 islets (90 to 155 per donor). 
B. tSNE visualization of islets, as in Figure 3A, color-coded by donor (nPOD case IDs and T1D stages are indicated 
on the right). 
C. Islet pseudotime (left) and pseudostages (right) overlaid on the SCORPIUS map. n = 1494 islets (90 to 155 per 
donor). 
D. Evolution of islet markers expression levels through pseudotime progression overlaid on the SCORPIUS map. 
E. Violin plots showing pseudotime distribution for individual donors (one dot = one islet, the number of islets per 
donor, n, is indicated on top of the plot). Pseudostages, as defined in Figure 3D, are indicated in blue and pseudostage 
separation is indicated by horizontal blue lines.  
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Figure S5. Islet and β Cell Pseudotime Analysis (legend on next page)
Figure S5. Islet and β Cell Pseudotime Analysis. Related to Figure 3 
A. Evolution of β cell marker expression in individual β cells through pseudostages. Same data as in Figure 3G shown 
at the β cell level to visualize β cell heterogeneity. Number of β cells analyzed: pseudostage 1, n = 38,479 β cells; 
pseudostage 2, n = 16,103 β cells; pseudostage 3, n = 618 β cells. 
B. Pseudotime analysis of islet expression profiles using Monocle2. Ordering was performed based on the expression 
of islet markers (one dot = one islet, n = 1494 islets). The black line represents the trajectory computed by Monocle2. 
C. Heatmap showing the expression levels of islet markers. Columns represent individual islets arranged according to 
pseudotime progression (computed with Monocle2). Horizontal bars on top indicate donor stage and islet pseudotime. 
D. Violin plots showing islet distribution over pseudotime for controls and donors with T1D (left). Pseudostage 
separations are based on the density distribution of islets over Moncole2-computed pseudotime (right) and are 
indicated by horizontal blue lines. Pseudostages are indicated in blue. 
E. Islet β cell fraction, as measured for the three Monocle2-defined pseudostages. 
F. Islet extent and solidity measured for each Monocle2-defined pseudostage. Pairwise comparisons of the three 
pseudostages: *, P < 0.01; **, P < 0.001; ***, P < 0.0001, n.s., not significant (Mann-Whitney U test with Holm 
adjustment). 
G. Evolution of β cell markers expression in β cells through Monocle2-defined pseudostages. Expression levels were 
measured in individual β cells and averaged for each islet. Pairwise comparisons of the three pseudostages: *, P < 
0.01; **, P < 0.001; ***, P < 0.0001, n.s., not significant (Mann-Whitney U test with Holm adjustment). 
H. Hierarchical clustering of pancreas donors based on the expression of islet markers measured at the β cell level. 
The disease stage of each donor is color-coded on the left and nPOD case IDs are indicated on the right. 
J. tSNE map representing the expression profiles of β cells from 12 donors at different stages of T1D (one dot = one 
β cell). 
K. Violin plots showing β cell distribution over SCORPIUS-computed pseudotime for the three disease stages. Dots 
represent individual β cells. 
L. Heatmap showing expression of β cell markers with columns representing β cells arranged according to pseudotime 
progression. Horizontal bars on the top of the heatmap indicate donor disease stage and pseudotime. 
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Figure S6. Distribution of Immune Cell Types per Donor (legend on next page)
Figure S6. Distribution of Immune Cell Types per Donor. Related to Figure 4 
A. Density of immune cell types over IMC images measured for each donor. For each cell type, cell densities for 
individual donors with T1D were compared to the average value for non-diabetic donors (Mann-Whitney U test with 
Holm adjustment; *, P < 0.01; **, P < 0.001; ***, P < 0.0001; n.s., not significant). 
B. Average number of immune cells over binned distance to islet rim measured for each donor. Cell fractions are 
normalized by cell type. One bin corresponds to a distance of 10 μm with negative and positive values representing 
bins located outside and inside islets, respectively. The dotted vertical lines indicate the islet rim. Arrows indicate 
increased Tc and Th cell numbers around islets from nPOD case 6414. B cells and naïve Tc cells were not numerous 
enough to be meaningfully plotted. Error bars, SEM. 
C. Fraction of islets containing given numbers of associated immune cells (inside the islet or within 20 μm of the islet 
rim), for all analyzed cell types, in function of the disease stage and pseudostage. 
 
Table S1. Human Donors: Clinical Data. Related to STAR Methods 
 
nPOD 
case ID 
Group for 
data 
analysis 
Imaged 
pancreas 
regions 
Matched 
group 
Age 
(years) Gender Race BMI Donor type 
Diabetes 
duration 
(years) 
6126 Non-diabetic 
Tail 
Body 1 25.2 Male Caucasian 25.1 Non-diabetic - 
6134 Non-diabetic 
Tail 
Body 2 26.7 Male Caucasian 20.1 Non-diabetic - 
6386 Non-diabetic 
Tail 
Body 3 14 Male Caucasian 23.9 Non-diabetic - 
6278 Non-diabetic 
Tail 
Body 4 12 Female 
African- 
American 21.3 Non-diabetic - 
6362 Onset 
Tail 
Body 1 24.9 Male Caucasian 28.5 T1D 
0.0 
(7.75 days) 
6414 Onset 
Tail 
Body 2 23.1 Male 
African- 
American 24.3 T1D 0.4 
6228 Onset 
Tail 
Body 3 13.0 Male Caucasian 17.4 T1D 
0.0 
(9.5 days) 
6380 Onset 
Tail 
Body 4 11.6 Female 
African- 
American 14.6 T1D 
0.0 
(2 days) 
6418 Long-duration 
Tail 
Body 1 24.9 Male Caucasian 26.4 T1D 11 
6180 Long-duration 
Tail 
Body 2 27 Male Caucasian 25.9 T1D 11 
6089 Long-duration 
Tail 
Body 3 14.3 Male Caucasian 26.0 T1D 8 
6264 Long-duration 
Tail 
Head 4 12 Female Caucasian 22.0 T1D 9 
 
 
  
nPOD 
case ID 
Auto-antibody 
status 
C-peptide 
(ng/mL) 
HbA1c 
(%) 
Pancreas 
weight (g) HLA 
6126 Negative 0.88 N/A 80.2 A*29:02,33:01;DRB1*03:01,07:01;DQA1*02:01,05:01 DQB1*02:01,02:01 
6134 Negative 3.59 N/A 82.4 A*03:01,29:02; DRB1*07:01,10:01; DQA1*01:01,02:01; DQB1*02:01,05:01 
6386 Negative 1.12 5.6 61.4 
A*02:01, 
03:01;DRB1*04:04,13:01;DQA1*01:03,03:01;DQB
1*03:02,06:03 
6278 Negative 4.54 6.3 33.6 A*23:01,68:02 DRB1*11:04,12:01 DQA1*03:01,05:01 DQB1*03:01,05:02 
6362 GADA+ 0.38 10.0 53.3 A*03:01,11:01;DRB1*01:03,03:01; DQA1*01:01,05:01;DQB1*02:01,05:01 
6414 GADA+ ZnT8+ mIAA+ 0.16 14.0 98.5 
DRB1*03:01,09:01;DQA1*05:01,03:03;DQB1*02:
01,02:02 
6228 GADA+ ZnT8+ IA-2A+ 0.10 13.3 N/A 
A*23:01, 68:01;DRB1*03:01, 04:02;DQA1*03:01, 
05:01;DQB1*02:01, 03:02 
6380 Negative 0.22 13.5 34.3 
A*33:03,68:02; 
DRB1*03:01,13:02;DQA1*01:02,05:01; 
DQB1*02:01,06:04 
6418 GADA+ ZnT8+ IA-2A+ mIAA+ < 0.02 7.5 28.6 A*02/32 B*51/62 DR*04/11 DQ*07/08 
6180 GADA+ ZnT8+ IA-2A+ mIAA+ < 0.05 N/A 36.7 
A*01:01,02:01; DRB1*01:01 ,03:01; DQA1*01:01 
,05:01; DQB1*02:01 , 05:01 
6089 mIAA+ < 0.05 10.4 56.8 A*01:01,02:01; DRB1*01:01,04:01; DQA1*01:01,03:01; DQB1*03:02,05:01 
6264 Negative < 0.05 8.9 20.4 A*23:01,32:01; DRB1*03:01 ,04:04;DQA1*03:01 ,05:01;DQB1*02:01,03:02 
 
  
nPOD 
case ID 
Diabetes 
medications 
taken 
Peak glucose 
during hospital 
stay (mg/dL) 
Lipase 
(U/L) 
Amylase 
(U/L) 
Hospitalization 
stay days Cause of death 
6126 None 272 546 164 4.88 Head trauma 
6134 None N/A 40 175 2.02 Anoxia 
6386 None 198 N/A N/A 2.34 Head trauma 
6278 None 395 11 100 1.84 Anoxia 
6362 Insulin IV (drip) on admission 435 N/A N/A 7.76 Head trauma 
6414 NovoLog  Lantus 690 N/A N/A 4.63 Anoxia 
6228 None 664 45 33 10.04 Anoxia 
6380 None 1661 N/A N/A 4.02 
Diabetes 
ketoacidosis, 
Cerebral edema 
6418 Insulin (injections and pump) 400 N/A N/A 5.25 Anoxia 
6180 NovoLog (pump) 363 14 26 5.53 Head trauma 
6089 Humalog Lantus 750 3000 736 2.79 Anoxia 
6264 
Humalog 
NovoLog 
Lantus 
641 N/A N/A 2.13 Diabetic ketoacidosis 
 
Table S2. Antibody Validation. Related to STAR Methods 
 
PANCREAS 
Short name Target protein Evidence for antibody validation 
INS Insulin 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies 
and has been used in many (>20) studies.  
Our observations - Pancreas: Detected in islets only, in the same cells as proinsulin, amylin and 
Nkx6.1. No colocalization with other pancreatic hormones. 
Other tissues: Not detected 
PIN Proinsulin 
This antibody reacts with the site of connection of C-peptide and C-end of B-chain of proinsulin 
molecule. It is validated for IHC by Abcam and has been used in several studies. 
Our observations - Pancreas: Detected in islets only, in the same cells as insulin, amylin and 
Nkx6.1, but with a slightly different subcellular distribution as compared to insulin. No colocalization 
with other pancreatic hormones. 
Other tissues: Not detected 
GCG Glucagon 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies 
and has been used in several studies. 
Our observations - Pancreas: Detected in islets only, no colocalization with other pancreatic 
hormones. 
Other tissues: Detected in duodenum enteroendocrine cells (proglucagon) 
SST Somatostatin 
This antibody is validated for IHC by Dako and has been used in many studies. 
Our observations - Pancreas: Detected in islets only, no colocalization with other pancreatic 
hormones. 
Other tissues: Detected in duodenum and colonic enteroendocrine cells. 
PPY Pancreatic polypeptide 
This antibody is validated for IHC on paraffin-embedded sections by R&D Systems. 
Our observations - Pancreas: Detected in islets only, no colocalization with other pancreatic 
hormones. 
Other tissues: Not detected 
NKX6-1 Nkx6.1 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies. 
Our observations - Pancreas: Detected in islets only, in cells positive for (pro-)insulin. Nuclear 
expression pattern. 
Other tissues: Not detected. 
PDX1 
Goat IgG 
(goat anti-Pdx1) 
This antibody is validated for IHC on paraffin-embedded sections by R&D Systems and has been 
used in several studies.  
Our observations - Pancreas: Detected in islets, in cells positive for (pro-)insulin and 
somatostatin. Also expressed in pancreatic ductal cells. Signal stronger in nucleus than in 
cytoplasm. 
Other tissues: Positive cells observed in the duodenum. Also observed in enteroendocrine cells in 
the colon (together with somatostatin). Background signal observed in several tissues. 
IAPP Amylin 
This antibody is validated for IHC on paraffin-embedded sections by Sigma and additionally 
validated for the Human Protein Atlas project. 
Our observations - Pancreas: Detected in islets only, in the same cells as (pro-)insulin. No 
colocalization with pancreatic hormones.  
Other tissues: Background signal detected in a few tissues (skeletal muscle, duodenum, placenta). 
PCSK2 Prohormone convertase 2 
This antibody is validated for IHC by Merck. 
Our observations - Pancreas: Detected in islets only. Signal highest in α cells. 
Other tissues: Positive cells observed in duodenum. Background signal observed in several 
tissues. 
SYP Synaptophysin 
This antibody is validated for IHC on paraffin-embedded sections by Abcam and has been used in 
many studies. 
Our observations - Pancreas: Detected in islets, overlap with pancreatic hormones and with 
CD99. Also detected in pancreatic neuroendocrine carcinoma. 
Other tissues: High levels detected in cerebral cortex. 
  
CD99 CD99 
This antibody is validated for IHC on paraffin-embedded sections by BioLegend. 
Our observations - Pancreas: Very high signal in islets, overlaps with synaptophysin. Detected at 
much lower levels in exocrine cells and some immune cells. Also detected in pancreatic 
neuroendocrine carcinoma. 
Other tissues: Detected in a wide range of tissues. High levels observed in spleen. 
SLC2A1 
Glucose 
transporter 1 
This antibody is validated for IHC on paraffin-embedded sections by Abcam and has been used in 
many studies. 
Our observations - Pancreas: Highest signal observed in islet cells. 
Other tissues: High signal in endothelial cells of the cerebral cortex and in the microvillus and 
basal membranes of the placenta. High signal in several cancer samples (urothelial, breast and 
ovarian carcinoma; lung, uterus and colorectal mucinous adenocarcinoma; melanoma). 
PTPRN 
Receptor-type 
tyrosine-protein 
phosphatase-like N 
This antibody is validated for IHC on paraffin-embedded sections by Sigma and additionally 
validated for the Human Protein Atlas project. 
Our observations - Pancreas: Detected in all islet cells. 
Other tissues: Detected in the enteric neuronal cells in the muscular layers of the duodenum 
(colocalized with Synaptophysin). 
AMY2A Pancreatic amylase 
This antibody is validated for IHC on paraffin-embedded sections by Abcam and has been used in 
several studies. 
Our observations - Pancreas: Detected only in exocrine tissue. Staining pattern consistent with 
acinar cells. No overlap with islet and ductal (KRT19) markers. 
Other tissues: Not detected. 
KRT19 Cytokeratin 19 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies. 
Our observations - Pancreas: Detected only in exocrine tissue. Staining pattern consistent with 
ductal cells. Detected in the same cells as Sox9 in a parallel experiment. 
Other tissues: Detected in colon and uterus epithelial cells, and in kidney tubules 
CD44 CD44 
This clone is validated for IHC on paraffin-embedded sections by BD Biosciences and has been 
used in many studies. 
Our observations - Pancreas: Detected in subsets of exocrine cells and in some immune cells. 
Other tissues: Detected in large subsets of immune cells and in a wide range of tissues.  
  
IMMUNE 
Short name Target protein Evidence for antibody validation 
CD45 CD45 
This antibody is validated for IHC on paraffin-embedded sections by eBioscience and has been 
used in several studies. 
Our observations: Staining pattern consistent with immune cells in lymphoid and other tissues. 
CD45RA CD45RA 
This clone is validated for CyTOF and IHC by Biolegend, Fluidigm and other companies and was 
internally validated by suspension mass cytometry. It has been used in many studies. 
Our observations: In the pancreas, detected in B cells and in a subset of T cells. In lymphoid 
tissues, detected in B cells and in subsets of other immune cells. 
CD3e CD3ε 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies. 
Our observations: detected in a subset of CD45-positive cells. Colocalized with either CD4 or CD8 
in the pancreas and in lymphoid tissues. Staining pattern in lymphoid tissues consistent with T cells. 
CD4 CD4 
This antibody is validated for IHC on paraffin-embedded sections by R&D Systems and has been 
used in several studies. 
Our observations: Detected in a subset of CD45+ CD3e+ cells in the pancreas and in lymphoid 
tissues. No overlap with CD8a observed. 
CD8a CD8a 
This clone is validated for IHC on paraffin-embedded sections by eBioscience and other companies, 
and has been used in many studies. 
Our observations: Detected in a subset of CD45+ CD3e+ cells in the pancreas and in lymphoid 
tissues. No overlap with CD4 observed. 
CD20 CD20 
This clone is validated for IHC on paraffin-embedded sections by eBioscience and other companies, 
and has been used in many studies. 
Our observations: Detected in a subset of CD45+ cells in the pancreas and lymphoid tissues. 
Staining pattern in lymphoid tissues consistent with B cells. 
  
CD68 CD68 
This clone is validated for IHC on paraffin-embedded sections by eBioscience and other companies, 
and has been used in many studies. 
Our observations: Expression pattern consistent with macrophages/monocytes in internal cross-
validations with anti-CD163 and anti-CD16 antibodies. Also detected in fibroblasts, which has been 
reported for this clone.  
MPO Myeloperoxidase 
This antibody is validated for IHC on paraffin-embedded sections by Dako and has been used in 
many studies. 
Our observations: Staining pattern consistent with neutrophils in the spleen. 
FOXP3 Forkhead box P3 
This clone is validated for IHC on paraffin-embedded sections by eBioscience and other companies, 
and was internally validated by suspension mass cytometry. It has been used in many studies. 
Our observations: Nuclear signal observed in a small subset of CD4+ cells. 
CD38 CD38 
This antibody is validated for IHC on paraffin-embedded sections by Abcam and was internally 
validated by suspension mass cytometry. It has been used in several studies. 
Our observations: Expressed in a wide range of cells and tissues. 
  
MISC 
Short name Target protein Evidence for antibody validation 
CDH E-/P-cadherin 
This antibody is validated for IHC by BD Biosciences and has been used in many studies. 
Our observations: Detected in both exocrine and islet cells in the pancreas. Staining pattern 
consistent with epithelial cells in all tissues analyzed. 
CD31 CD31 
This antibody is validated for IHC on paraffin-embedded sections by Novus and has been used in 
many studies. 
Our observations: Pattern consistent with endothelial cells in all tissues analyzed. SMA staining 
often detected around large CD31+ blood vessels. 
SMA Smooth muscle actin 
This antibody is validated for IHC on paraffin-embedded sections by Abcam and has been used in 
several studies. 
Our observations: Detected in smooth muscle. Signal also commonly observed around large 
blood vessels. 
KI-67 Ki-67 
This antibody is validated for bioimaging by BD Biosciences and has been used in many studies. 
Our observations: Nuclear expression pattern, consistent with proliferating cells in all tissues 
analyzed. Often colocalized with pRB1. 
pH3 Phospho-histone H3 
This clone is validated for IHC on paraffin-embedded sections and CyTOF by Biolegend, Fluidigm 
and other companies. It has been used in many studies. 
Our observations: Nuclear staining pattern. Sometimes colocalized with Ki-67. Unspecific signal in 
skeletal muscle (sarcomeres) but the signal is clearly distinct from the nuclear signal observed in 
dividing cells. 
pRB1 Phospho-retinoblastoma 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies 
and has been used in many studies. 
Our observations: Staining pattern consistent with cycling cells. Often colocalizes with Ki-67. 
cPARP1 
Cleaved caspase 3 
+ poly (ADP-ribose) 
polymerase 
These anti-caspase 3 antibody is validated for IHC on paraffin-embedded sections by BD 
biosciences and has been used in many studies. Both antibodies have been validated internally for 
suspension and imaging mass cytometry. 
Our observations: Very few positive cells observed in all analyzed tissues.  
CA9 Carbonic anhydrase IX 
This antibody is validated for IHC on paraffin-embedded sections by R&D Systems and has been 
used in several studies. 
Our observations: Detected in duodenum crypt cells and in several cancer samples (e.g. clear 
renal cells and urothelial cell carcinoma) 
H3 Histone H3 
This antibody is validated for IHC on paraffin-embedded sections by Cell Signaling Technologies 
and has been used in many studies. 
Our observations: Detected only in nuclei, in all tissues analyzed. 
 
